Reviva Pharmaceuticals (RVPH)

Executive Summary

Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapies for CNS, cardiovascular, metabolic, and inflammatory diseases. Its lead candidate, brilaroxazine (RP5063), is a multimodal serotonin-dopamine stabilizer being investigated for schizophrenia and other neuropsychiatric disorders. The company completed a Phase 2 trial for acute schizophrenia and has a Phase 3 RECOVER trial (NCT05184335) evaluating brilaroxazine in schizophrenia, which completed enrollment. Reviva also has potential for brilaroxazine in bipolar disorder and major depressive disorder, supported by preclinical and early clinical data. Reviva's near-term value hinges on the success of brilaroxazine in schizophrenia. The Phase 3 RECOVER trial topline results are expected in Q3 2025, followed by an NDA submission if positive. Additionally, the company may initiate Phase 3 trials for other indications such as bipolar disorder. A potential partnership for brilaroxazine outside the US could also drive value. With a strong safety profile and differentiated mechanism, brilaroxazine has blockbuster potential, but execution risks and competition remain.

Upcoming Catalysts (preview)

• Q3 2025Phase 3 RECOVER Topline Data Readout for Brilaroxazine in Schizophrenia70% success
• Q1 2026NDA Submission for Brilaroxazine in Schizophrenia50% success
• Q4 2025Initiation of Phase 3 Program for Brilaroxazine in Bipolar Disorder30% success